The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient‐derived data
Background and purpose The cost of medication overuse headache (MOH) is underestimated. Our aim was to address the cost‐effectiveness of a structured treatment protocol and to present annual cost estimates. Methods Patients were enrolled on the occasion of a structured treatment protocol, were admin...
Gespeichert in:
| Veröffentlicht in: | European journal of neurology 2020-01, Vol.27 (1), p.62-e1 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1 |
|---|---|
| container_issue | 1 |
| container_start_page | 62 |
| container_title | European journal of neurology |
| container_volume | 27 |
| creator | Raggi, A. Leonardi, M. Sansone, E. Curone, M. Grazzi, L. D'Amico, D. |
| description | Background and purpose
The cost of medication overuse headache (MOH) is underestimated. Our aim was to address the cost‐effectiveness of a structured treatment protocol and to present annual cost estimates.
Methods
Patients were enrolled on the occasion of a structured treatment protocol, were administered a research protocol addressing direct and indirect costs and were followed up for 3 months.
Results
Of 176 enrolled patients, 138 completed the study. The 3‐month cost per patient fell from €2989 to €1160: the difference was €696 per month for patients treated in the ward and €466 for those treated in day‐hospital; thus it takes 2–3 months to compensate for the protocol's cost. The per‐person annual costs of MOH were €10 533 (95% confidence interval €8700–12 406): direct healthcare costs accounted for 44.8% and indirect costs for 51.5% of the total MOH cost. The annual MOH cost for Italy is estimated at €13.5 billion (95% confidence interval €11.1–15.9 billion).
Conclusion
The cost of MOH around the period of a structured treatment protocol is much higher compared to previous estimates. Our protocol is cost‐effective for reducing the economic burden of MOH. |
| doi_str_mv | 10.1111/ene.14034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2256105028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2322135991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3884-f57243f7695595204c4cb3945935eeff86f24a4a7fb6000b4c790911d28c10f83</originalsourceid><addsrcrecordid>eNp1kc9O3DAQxi3UqlDooS9QWeqFHgL-m8TcEFpaJNRe4Bw5zhiMsvFiO4v21r4Bz9gn6WyX9lCpvnhm9Ps-aeYj5D1nJxzfKUxwwhWTao8ccFW3FZeSv8Jaal5pzvg-eZvzA2NMNIK9IfuSC8OVUQfkx809UBdzoXYaaMFmbccZaPS0JLBlCVPZNksYgrMlxInGNaQ5A70HO1iHijDRq2LHzRm1dIzTXSjzECY70ozFhvY2w0BRuEI92v38_jxACmscDrbYI_La2zHDu5f_kNxeLm4uvlTX3z5fXZxfV062raq8boSSvqmN1kYLppxyvTRKG6kBvG9rL5RVtvF9jYv2yjWGGc4H0TrOfCsPyfHOd5Xi4wy5dMuQHYyjnSDOuRNC15xpJrbox3_Qhzgn3AgpKQSe1RiO1Kcd5VLMOYHvViksbdp0nHXbXDrMpfudC7IfXhznHk_5l_wTBAKnO-ApjLD5v1O3-LrYWf4C8b6XEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322135991</pqid></control><display><type>article</type><title>The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient‐derived data</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Raggi, A. ; Leonardi, M. ; Sansone, E. ; Curone, M. ; Grazzi, L. ; D'Amico, D.</creator><creatorcontrib>Raggi, A. ; Leonardi, M. ; Sansone, E. ; Curone, M. ; Grazzi, L. ; D'Amico, D.</creatorcontrib><description>Background and purpose
The cost of medication overuse headache (MOH) is underestimated. Our aim was to address the cost‐effectiveness of a structured treatment protocol and to present annual cost estimates.
Methods
Patients were enrolled on the occasion of a structured treatment protocol, were administered a research protocol addressing direct and indirect costs and were followed up for 3 months.
Results
Of 176 enrolled patients, 138 completed the study. The 3‐month cost per patient fell from €2989 to €1160: the difference was €696 per month for patients treated in the ward and €466 for those treated in day‐hospital; thus it takes 2–3 months to compensate for the protocol's cost. The per‐person annual costs of MOH were €10 533 (95% confidence interval €8700–12 406): direct healthcare costs accounted for 44.8% and indirect costs for 51.5% of the total MOH cost. The annual MOH cost for Italy is estimated at €13.5 billion (95% confidence interval €11.1–15.9 billion).
Conclusion
The cost of MOH around the period of a structured treatment protocol is much higher compared to previous estimates. Our protocol is cost‐effective for reducing the economic burden of MOH.</description><identifier>ISSN: 1351-5101</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/ene.14034</identifier><identifier>PMID: 31291494</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adult ; Analgesics - economics ; Analgesics - therapeutic use ; burden ; chronic migraine ; chronic tension‐type headache ; Confidence intervals ; Correlation analysis ; cost ; Cost estimates ; Costs ; detoxification ; Female ; Headache ; Headache Disorders, Secondary - economics ; Headache Disorders, Secondary - therapy ; Health Care Costs ; Humans ; Italy ; Longitudinal Studies ; Male ; medication overuse headache ; Middle Aged ; non‐pharmacological treatment ; Patients ; withdrawal</subject><ispartof>European journal of neurology, 2020-01, Vol.27 (1), p.62-e1</ispartof><rights>European Academy of Neurology 2019</rights><rights>European Academy of Neurology 2019.</rights><rights>Copyright © 2020 European Academy of Neurology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3884-f57243f7695595204c4cb3945935eeff86f24a4a7fb6000b4c790911d28c10f83</citedby><cites>FETCH-LOGICAL-c3884-f57243f7695595204c4cb3945935eeff86f24a4a7fb6000b4c790911d28c10f83</cites><orcidid>0000-0002-7433-7779</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fene.14034$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fene.14034$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31291494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raggi, A.</creatorcontrib><creatorcontrib>Leonardi, M.</creatorcontrib><creatorcontrib>Sansone, E.</creatorcontrib><creatorcontrib>Curone, M.</creatorcontrib><creatorcontrib>Grazzi, L.</creatorcontrib><creatorcontrib>D'Amico, D.</creatorcontrib><title>The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient‐derived data</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background and purpose
The cost of medication overuse headache (MOH) is underestimated. Our aim was to address the cost‐effectiveness of a structured treatment protocol and to present annual cost estimates.
Methods
Patients were enrolled on the occasion of a structured treatment protocol, were administered a research protocol addressing direct and indirect costs and were followed up for 3 months.
Results
Of 176 enrolled patients, 138 completed the study. The 3‐month cost per patient fell from €2989 to €1160: the difference was €696 per month for patients treated in the ward and €466 for those treated in day‐hospital; thus it takes 2–3 months to compensate for the protocol's cost. The per‐person annual costs of MOH were €10 533 (95% confidence interval €8700–12 406): direct healthcare costs accounted for 44.8% and indirect costs for 51.5% of the total MOH cost. The annual MOH cost for Italy is estimated at €13.5 billion (95% confidence interval €11.1–15.9 billion).
Conclusion
The cost of MOH around the period of a structured treatment protocol is much higher compared to previous estimates. Our protocol is cost‐effective for reducing the economic burden of MOH.</description><subject>Adult</subject><subject>Analgesics - economics</subject><subject>Analgesics - therapeutic use</subject><subject>burden</subject><subject>chronic migraine</subject><subject>chronic tension‐type headache</subject><subject>Confidence intervals</subject><subject>Correlation analysis</subject><subject>cost</subject><subject>Cost estimates</subject><subject>Costs</subject><subject>detoxification</subject><subject>Female</subject><subject>Headache</subject><subject>Headache Disorders, Secondary - economics</subject><subject>Headache Disorders, Secondary - therapy</subject><subject>Health Care Costs</subject><subject>Humans</subject><subject>Italy</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>medication overuse headache</subject><subject>Middle Aged</subject><subject>non‐pharmacological treatment</subject><subject>Patients</subject><subject>withdrawal</subject><issn>1351-5101</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9O3DAQxi3UqlDooS9QWeqFHgL-m8TcEFpaJNRe4Bw5zhiMsvFiO4v21r4Bz9gn6WyX9lCpvnhm9Ps-aeYj5D1nJxzfKUxwwhWTao8ccFW3FZeSv8Jaal5pzvg-eZvzA2NMNIK9IfuSC8OVUQfkx809UBdzoXYaaMFmbccZaPS0JLBlCVPZNksYgrMlxInGNaQ5A70HO1iHijDRq2LHzRm1dIzTXSjzECY70ozFhvY2w0BRuEI92v38_jxACmscDrbYI_La2zHDu5f_kNxeLm4uvlTX3z5fXZxfV062raq8boSSvqmN1kYLppxyvTRKG6kBvG9rL5RVtvF9jYv2yjWGGc4H0TrOfCsPyfHOd5Xi4wy5dMuQHYyjnSDOuRNC15xpJrbox3_Qhzgn3AgpKQSe1RiO1Kcd5VLMOYHvViksbdp0nHXbXDrMpfudC7IfXhznHk_5l_wTBAKnO-ApjLD5v1O3-LrYWf4C8b6XEw</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Raggi, A.</creator><creator>Leonardi, M.</creator><creator>Sansone, E.</creator><creator>Curone, M.</creator><creator>Grazzi, L.</creator><creator>D'Amico, D.</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7433-7779</orcidid></search><sort><creationdate>202001</creationdate><title>The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient‐derived data</title><author>Raggi, A. ; Leonardi, M. ; Sansone, E. ; Curone, M. ; Grazzi, L. ; D'Amico, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3884-f57243f7695595204c4cb3945935eeff86f24a4a7fb6000b4c790911d28c10f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Analgesics - economics</topic><topic>Analgesics - therapeutic use</topic><topic>burden</topic><topic>chronic migraine</topic><topic>chronic tension‐type headache</topic><topic>Confidence intervals</topic><topic>Correlation analysis</topic><topic>cost</topic><topic>Cost estimates</topic><topic>Costs</topic><topic>detoxification</topic><topic>Female</topic><topic>Headache</topic><topic>Headache Disorders, Secondary - economics</topic><topic>Headache Disorders, Secondary - therapy</topic><topic>Health Care Costs</topic><topic>Humans</topic><topic>Italy</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>medication overuse headache</topic><topic>Middle Aged</topic><topic>non‐pharmacological treatment</topic><topic>Patients</topic><topic>withdrawal</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raggi, A.</creatorcontrib><creatorcontrib>Leonardi, M.</creatorcontrib><creatorcontrib>Sansone, E.</creatorcontrib><creatorcontrib>Curone, M.</creatorcontrib><creatorcontrib>Grazzi, L.</creatorcontrib><creatorcontrib>D'Amico, D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raggi, A.</au><au>Leonardi, M.</au><au>Sansone, E.</au><au>Curone, M.</au><au>Grazzi, L.</au><au>D'Amico, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient‐derived data</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2020-01</date><risdate>2020</risdate><volume>27</volume><issue>1</issue><spage>62</spage><epage>e1</epage><pages>62-e1</pages><issn>1351-5101</issn><eissn>1468-1331</eissn><abstract>Background and purpose
The cost of medication overuse headache (MOH) is underestimated. Our aim was to address the cost‐effectiveness of a structured treatment protocol and to present annual cost estimates.
Methods
Patients were enrolled on the occasion of a structured treatment protocol, were administered a research protocol addressing direct and indirect costs and were followed up for 3 months.
Results
Of 176 enrolled patients, 138 completed the study. The 3‐month cost per patient fell from €2989 to €1160: the difference was €696 per month for patients treated in the ward and €466 for those treated in day‐hospital; thus it takes 2–3 months to compensate for the protocol's cost. The per‐person annual costs of MOH were €10 533 (95% confidence interval €8700–12 406): direct healthcare costs accounted for 44.8% and indirect costs for 51.5% of the total MOH cost. The annual MOH cost for Italy is estimated at €13.5 billion (95% confidence interval €11.1–15.9 billion).
Conclusion
The cost of MOH around the period of a structured treatment protocol is much higher compared to previous estimates. Our protocol is cost‐effective for reducing the economic burden of MOH.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>31291494</pmid><doi>10.1111/ene.14034</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-7433-7779</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-5101 |
| ispartof | European journal of neurology, 2020-01, Vol.27 (1), p.62-e1 |
| issn | 1351-5101 1468-1331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2256105028 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Analgesics - economics Analgesics - therapeutic use burden chronic migraine chronic tension‐type headache Confidence intervals Correlation analysis cost Cost estimates Costs detoxification Female Headache Headache Disorders, Secondary - economics Headache Disorders, Secondary - therapy Health Care Costs Humans Italy Longitudinal Studies Male medication overuse headache Middle Aged non‐pharmacological treatment Patients withdrawal |
| title | The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient‐derived data |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T20%3A13%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20cost%20and%20the%20value%20of%20treatment%20of%20medication%20overuse%20headache%20in%20Italy:%20a%20longitudinal%20study%20based%20on%20patient%E2%80%90derived%20data&rft.jtitle=European%20journal%20of%20neurology&rft.au=Raggi,%20A.&rft.date=2020-01&rft.volume=27&rft.issue=1&rft.spage=62&rft.epage=e1&rft.pages=62-e1&rft.issn=1351-5101&rft.eissn=1468-1331&rft_id=info:doi/10.1111/ene.14034&rft_dat=%3Cproquest_cross%3E2322135991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2322135991&rft_id=info:pmid/31291494&rfr_iscdi=true |